| scholarly article | Q13442814 |
| P356 | DOI | 10.2217/FON-2017-0597 |
| P8608 | Fatcat ID | release_vfe7fkp255ewpkx34gvbbxuove |
| P932 | PMC publication ID | 5925434 |
| P698 | PubMed publication ID | 29542354 |
| P50 | author | Ignacio Garrido-Laguna | Q71791712 |
| P2093 | author name string | Benjamin L Solomon | |
| P2860 | cites work | Actual long-term outcome of extrahepatic bile duct cancer after surgical resection | Q24540287 |
| Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial | Q27851578 | ||
| Angiogenesis in cancer and other diseases | Q27861015 | ||
| Sorafenib in advanced hepatocellular carcinoma | Q27861075 | ||
| Radiofrequency ablation in Barrett's esophagus with dysplasia | Q28246453 | ||
| PD-1 Blockade in Tumors with Mismatch-Repair Deficiency | Q28262647 | ||
| Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial | Q29547903 | ||
| Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial | Q29617955 | ||
| Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma | Q29617957 | ||
| Tumour heterogeneity and cancer cell plasticity | Q29617990 | ||
| Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer | Q29619394 | ||
| HER2 screening data from ToGA: targeting HER2 in gastric and gastroesophageal junction cancer | Q30837184 | ||
| Sunitinib versus sorafenib in advanced hepatocellular cancer: results of a randomized phase III trial | Q33410643 | ||
| Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial | Q33423800 | ||
| Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2/3 study | Q33440401 | ||
| Safety and tolerability of the first-in-class agent CPI-613 in combination with modified FOLFIRINOX in patients with metastatic pancreatic cancer: a single-centre, open-label, dose-escalation, phase 1 trial | Q33441785 | ||
| Overexpression of the HER2/neu Gene: A New Therapeutic Possibility for Patients With Advanced Gallbladder Cancer | Q33557258 | ||
| HER2 status in colorectal cancer: its clinical significance and the relationship between HER2 gene amplification and expression | Q33690070 | ||
| Is postoperative adjuvant chemotherapy useful for gallbladder carcinoma? A phase III multicenter prospective randomized controlled trial in patients with resected pancreaticobiliary carcinoma | Q33961798 | ||
| SEARCH: a phase III, randomized, double-blind, placebo-controlled trial of sorafenib plus erlotinib in patients with advanced hepatocellular carcinoma. | Q50454368 | ||
| Fibroblast growth factor receptor 2 translocations in intrahepatic cholangiocarcinoma. | Q53050181 | ||
| Phase 2 trial of induction and concurrent chemoradiotherapy with weekly irinotecan and cisplatin followed by surgery for esophageal cancer. | Q53197682 | ||
| Genomic spectra of biliary tract cancer. | Q53390123 | ||
| Level of HER2 gene amplification predicts response and overall survival in HER2-positive advanced gastric cancer treated with trastuzumab. | Q54402875 | ||
| Preoperative Chemoradiotherapy for Esophageal or Junctional Cancer | Q57259796 | ||
| Long-term follow-up of complete Barrett's eradication endoscopic mucosal resection (CBE-EMR) for the treatment of high grade dysplasia and intramucosal carcinoma | Q80802072 | ||
| Long-term results of RTOG trial 8911 (USA Intergroup 113): a random assignment trial comparison of chemotherapy followed by surgery compared with surgery alone for esophageal cancer | Q80807888 | ||
| The role of transcatheter arterial embolization for patients with unresectable hepatocellular carcinoma: a nationwide, multicentre study evaluated by cancer stage | Q81531606 | ||
| Cetuximab in combination with chemoradiotherapy before surgery in patients with resectable, locally advanced esophageal carcinoma: a prospective, multicenter phase IB/II Trial (SAKK 75/06) | Q83128084 | ||
| Targeting metabolism in pancreatic cancer | Q88043031 | ||
| Irrelevance of microsatellite instability in the epidemiology of sporadic pancreatic ductal adenocarcinoma | Q34430572 | ||
| Phase II trial of preoperative irinotecan-cisplatin followed by concurrent irinotecan-cisplatin and radiotherapy for resectable locally advanced gastric and esophagogastric junction adenocarcinoma | Q34609127 | ||
| Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer | Q34618537 | ||
| Best supportive care compared with chemotherapy for unresectable gall bladder cancer: a randomized controlled study | Q34623625 | ||
| Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial | Q34632818 | ||
| Effect of everolimus on survival in advanced hepatocellular carcinoma after failure of sorafenib: the EVOLVE-1 randomized clinical trial | Q34663499 | ||
| Linifanib versus Sorafenib in patients with advanced hepatocellular carcinoma: results of a randomized phase III trial | Q34786090 | ||
| New routes to targeted therapy of intrahepatic cholangiocarcinomas revealed by next-generation sequencing | Q35100996 | ||
| Upregulation of PD-L1 and APE1 is associated with tumorigenesis and poor prognosis of gastric cancer | Q35113261 | ||
| Frequent mutation of isocitrate dehydrogenase (IDH)1 and IDH2 in cholangiocarcinoma identified through broad-based tumor genotyping | Q35705307 | ||
| SWOG S0809: A Phase II Intergroup Trial of Adjuvant Capecitabine and Gemcitabine Followed by Radiotherapy and Concurrent Capecitabine in Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma | Q35947011 | ||
| Treatment of locally advanced unresectable pancreatic cancer: a 10-year experience | Q36381222 | ||
| Correlation of human epidermal growth factor receptor 2 expression with clinicopathological characteristics and prognosis in gastric cancer | Q36770491 | ||
| Forty-Year Trends in Cholangiocarcinoma Incidence in the U.S.: Intrahepatic Disease on the Rise | Q36884411 | ||
| Peri-operative chemotherapy with or without bevacizumab in operable oesophagogastric adenocarcinoma (UK Medical Research Council ST03): primary analysis results of a multicentre, open-label, randomised phase 2-3 trial. | Q37681214 | ||
| Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial | Q38443385 | ||
| Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial | Q38785510 | ||
| Expert consensus document: Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA). | Q38812588 | ||
| Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial | Q38829062 | ||
| Chromosomal rearrangements involving the NTRK1 gene in colorectal carcinoma | Q38871839 | ||
| Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial | Q38994795 | ||
| Cancer Statistics, 2017. | Q39038674 | ||
| Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial | Q40231174 | ||
| Nivolumab treatment for oesophageal squamous-cell carcinoma: an open-label, multicentre, phase 2 trial | Q40289794 | ||
| Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLO | Q40487371 | ||
| Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial. | Q40645806 | ||
| Long-term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer | Q43273409 | ||
| Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: results from the randomized phase III BRISK-FL study | Q43691230 | ||
| Identification of Targetable ALK Rearrangements in Pancreatic Ductal Adenocarcinoma | Q44008742 | ||
| Pancreatic Cancer Genomes: Implications for Clinical Management and Therapeutic Development. | Q44128628 | ||
| Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed: results from the randomized phase III BRISK-PS study. | Q45980006 | ||
| Hypermutation In Pancreatic Cancer | Q46267270 | ||
| Potential regional differences for the tolerability profiles of fluoropyrimidines | Q46619796 | ||
| Comparison between endoscopic and surgical resection of mucosal esophageal adenocarcinoma in Barrett's esophagus at two high-volume centers | Q46723942 | ||
| Phase II Study of BGJ398 in Patients With FGFR-Altered Advanced Cholangiocarcinoma. | Q47403256 | ||
| Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial | Q47745009 | ||
| Sorafenib in combination with transarterial chemoembolisation in patients with unresectable hepatocellular carcinoma (TACE 2): a randomised placebo-controlled, double-blind, phase 3 trial. | Q47788877 | ||
| Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. | Q47826637 | ||
| Mismatch Repair Deficiency, Microsatellite Instability, and Survival: An Exploratory Analysis of the Medical Research Council Adjuvant Gastric Infusional Chemotherapy (MAGIC) Trial. | Q50331121 | ||
| P433 | issue | 10 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 947-962 | |
| P577 | publication date | 2018-03-15 | |
| P1433 | published in | Future Oncology | Q2781597 |
| P1476 | title | Upper gastrointestinal malignancies in 2017: current perspectives and future approaches. | |
| P478 | volume | 14 |
| Q92618614 | The combined expressions of B7H4 and ACOT4 in cancer-associated fibroblasts are related to poor prognosis in patients with gastric carcinoma | cites work | P2860 |
Search more.